Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

In 2022, nearly one million new patients were diagnosed with gastric cancer

- PMLiVE

Eisai submits new drug application for subcutaneous Leqembi in Japan

LEQEMBI is a treatment for early Alzheimer’s disease

- PMLiVE

Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

Around 9,000 people in the US currently live with SMA

- PMLiVE

Regeneron’s Libtayo receives EC approval for skin cancer

Phase 3 trial results showed the drug significantly improved disease-free survival

- PMLiVE

ESMO 2025 – ensuring innovation isn’t lost in translation

This year marks the congress’s 50th anniversary, with the theme: Many journeys. One global community

Printed version of 'The participation equation'

Behind the scenes: why we created ‘The participation equation’

Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research.

Cuttsy + Cuttsy

- PMLiVE

Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

Inizio

- PMLiVE

Sandoz launches first and only multiple sclerosis biosimilar in US

The treatment is FDA-approved to treat MS and Crohn’s disease

- PMLiVE

Tonix launches new oral fibromyalgia treatment

Tonmya is the first approved treatment for adults with fibromyalgia in over 15 years

R:SQD logo

Cuttsy+Cuttsy launches R:SQD – a new way to predict and improve trial success

Cuttsy+Cuttsy has launched R:SQD, an innovative recruitment and retention success scoring tool that helps clinical trial sponsors predict, measure, and improve participant engagement and trial outcomes.

Cuttsy + Cuttsy

- PMLiVE

Agility in medical affairs: responding to rapid market and regulatory shifts

By Maurice Leonard

- PMLiVE

Optimised therapy to improve outcomes for heart attack and stroke patients

Personalising therapy promises to revolutionise the treatment of thrombosis

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links